Literature DB >> 17726481

Splicing in disease: disruption of the splicing code and the decoding machinery.

Guey-Shin Wang1, Thomas A Cooper.   

Abstract

Human genes contain a dense array of diverse cis-acting elements that make up a code required for the expression of correctly spliced mRNAs. Alternative splicing generates a highly dynamic human proteome through networks of coordinated splicing events. Cis- and trans-acting mutations that disrupt the splicing code or the machinery required for splicing and its regulation have roles in various diseases, and recent studies have provided new insights into the mechanisms by which these effects occur. An unexpectedly large fraction of exonic mutations exhibit a primary pathogenic effect on splicing. Furthermore, normal genetic variation significantly contributes to disease severity and susceptibility by affecting splicing efficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726481     DOI: 10.1038/nrg2164

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  445 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.

Authors:  Jens Rauch; Kim Moran-Jones; Valerie Albrecht; Thomas Schwarzl; Keith Hunter; Olivier Gires; Walter Kolch
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

Review 3.  Biomedical impact of splicing mutations revealed through exome sequencing.

Authors:  Bahar Taneri; Esra Asilmaz; Terry Gaasterland
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

4.  TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription.

Authors:  Marta Montes; Alexandre Cloutier; Noemí Sánchez-Hernández; Laetitia Michelle; Bruno Lemieux; Marco Blanchette; Cristina Hernández-Munain; Benoit Chabot; Carlos Suñé
Journal:  Mol Cell Biol       Date:  2011-12-12       Impact factor: 4.272

Review 5.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

6.  Changes in exon-intron structure during vertebrate evolution affect the splicing pattern of exons.

Authors:  Sahar Gelfman; David Burstein; Osnat Penn; Anna Savchenko; Maayan Amit; Schraga Schwartz; Tal Pupko; Gil Ast
Journal:  Genome Res       Date:  2011-10-05       Impact factor: 9.043

7.  Chromatin density and splicing destiny: on the cross-talk between chromatin structure and splicing.

Authors:  Schraga Schwartz; Gil Ast
Journal:  EMBO J       Date:  2010-04-20       Impact factor: 11.598

8.  Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells.

Authors:  Huan-Huan Wei; Yuanlong Liu; Yang Wang; Qianyun Lu; Xuerong Yang; Jiefu Li; Zefeng Wang
Journal:  J Vis Exp       Date:  2017-04-26       Impact factor: 1.355

9.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart.

Authors:  Auinash Kalsotra; Xinshu Xiao; Amanda J Ward; John C Castle; Jason M Johnson; Christopher B Burge; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Impact of human pathogenic micro-insertions and micro-deletions on post-transcriptional regulation.

Authors:  Xinjun Zhang; Hai Lin; Huiying Zhao; Yangyang Hao; Matthew Mort; David N Cooper; Yaoqi Zhou; Yunlong Liu
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.